高剂量与标准剂量缩宫素用于初产妇引产增量的随机对照试验
这项双盲随机对照试验纳入1003名≥36周初产妇,比较高剂量(6 mU/min起始与增量)与标准剂量(2 mU/min)缩宫素用于引产增量。高剂量组未降低首次剖宫产率(14.5% vs 14.4%;RR 1.01,95%CI 0.75-1.37),但显著缩短平均产程(9.1 vs 10.5小时;P<.001)并降低临床绒毛膜羊膜炎发生率(10.4% vs 15.6%;RR 0.67,95%CI 0.48-0.92),围产结局无显著差异。
要点
- 高剂量缩宫素未降低初产妇引产增量的剖宫产风险。
- 两组围产结局无显著差异,脐动脉酸血症结果在多插补后不显著。
核心结论
- 在引产增量的初产妇中,高剂量缩宫素方案与标准剂量相比不改变剖宫产风险,但缩短产程并降低临床绒毛膜羊膜炎频率,且不增加围产不良结局。
研究设计与样本
- 双盲随机对照试验,纳入≥36周妊娠、正在接受引产增量的初产妇,高剂量组502例(起始与增量速率6 mU/min),标准剂量组501例(起始与增量速率2 mU/min)。
- 计划样本量每组501例(共1002例),以80%把握度检测主要结局从标准剂量组20%降至高剂量组13.4%的6.6%绝对降幅。
- 实际随机1003例,2015年9月至2020年9月纳入,多数参与者为白人种族、已婚或同居、拥有商业保险,两组基线特征相似。
主要发现
- 主要结局剖宫产率在高剂量组为14.5%,标准剂量组为14.4%(相对风险1.01;95%CI 0.75-1.37)。
- 高剂量组平均产程显著缩短(9.1 vs 10.5小时;P<.001)。
- 高剂量组临床绒毛膜羊膜炎发生率显著降低(10.4% vs 15.6%;相对风险0.67;95%CI 0.48-0.92)。
- 脐动脉酸血症在高剂量组完整病例分析中显著更少,但多重插补后不显著(相对风险0.55;95%CI 0.29-1.04)。
- 其他预设次要结局(子宫内膜炎、产后出血、5分钟Apgar≤3、新生儿ICU入住、围产死亡、严重围产病复合终点)组间无显著差异。
关键数值与推荐
- 高剂量缩宫素方案:起始和增量速率均为6 mU/min;标准剂量方案:起始和增量速率均为2 mU/min。
- 主要结局剖宫产率:高剂量组14.5% vs 标准剂量组14.4%(RR 1.01;95%CI 0.75-1.37)。
- 临床绒毛膜羊膜炎:高剂量组10.4% vs 标准剂量组15.6%(RR 0.67;95%CI 0.48-0.92)。
- 平均产程:高剂量组9.1小时 vs 标准剂量组10.5小时(P<.001)。
临床怎么用
- 对于≥36周正在引产增量的初产妇,高剂量缩宫素方案可作为缩短产程和降低临床绒毛膜羊膜炎风险的选择,但不应期望降低剖宫产率。
- 临床决策时需结合个体情况权衡高剂量缩宫素对产程和感染指标的影响,围产安全性在本试验中未见显著差异。
局限性
- 研究人群以白人、已婚或同居、商业保险者为主,结果外推至其他人群需谨慎。
- 脐动脉酸血症的获益在多重插补后不显著,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether a high-dose oxytocin regimen reduces the risk for primary cesarean birth and other obstetric morbidities when compared with standard dosing. METHODS: In a double-blind randomized clinical trial of nulliparous women at or beyond 36 weeks of gestation who were undergoing augmentation of labor, participants were assigned to high-dose (initial and incremental rates of 6 milliunits/min) or standard-dose (initial and incremental rates of 2 milliunits/min) oxytocin regimens. The primary outcome was cesarean birth. Prespecified secondary outcomes included labor duration, clinical chorioamnionitis, endometritis, postpartum hemorrhage, Apgar score 3 or less at 5 minutes, umbilical artery acidemia, neonatal intensive care unit admission, perinatal death, and a severe perinatal morbidity composite. A sample size of 501 per group (n=1,002) was planned to detect a 6.6% absolute reduction in rate of the primary outcome, from 20% in the standard-dose group to 13.4% in the high-dose group with 80% power. RESULTS: From September 2015 to September 2020, 1,003 participants were randomized-502 assigned to high-dose and 501 assigned to standard dosing. The majority of participants were of White race, were married or living as married, and had commercial insurance. Baseline characteristics between groups were similar. The primary outcome occurred in 14.5% of those receiving high-dose compared with 14.4% of those receiving standard-dose oxytocin (relative risk, 1.01; 95% CI 0.75-1.37). The high-dose group had a significantly shorter mean labor duration (9.1 vs 10.5 hours; P<.001), and a significantly lower chorioamnionitis incidence (10.4% vs 15.6%; relative risk, 0.67; 95% CI 0.48-0.92) compared with standard dosing. Umbilical artery acidemia was significantly less frequent in the high-dose group in complete case analysis, but this finding did not persist after multiple imputation (relative risk, 0.55; 95% CI 0.29-1.04). There were no significant differences in other secondary outcomes. CONCLUSION: Among nulliparous participants who were undergoing augmentation of labor, a high-dose oxytocin regimen, compared with standard dosing, did not affect the cesarean birth risk but significantly reduced labor duration and clinical chorioamnionitis frequency without adverse effects on perinatal outcomes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02487797.
引用
- Son M, Roy A, Stetson BT, et al. High-Dose Compared With Standard-Dose Oxytocin Regimens to Augment Labor in Nulliparous Women: A Randomized Controlled Trial. Obstet Gynecol. 2021. PMID: 33957657. doi:10.1097/AOG.0000000000004399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。